Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Last trade$4.73
Day change-$0.09 (-1.87%)
Day range$4.65 – $4.87
Volume1,047,078
Market cap$383M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$383.37M
Price / earnings
6×
Price / book
0.83×
Price / sales
0.93×
EV / sales
0.07×
EV / EBITDA
0.14×
Profitability
Earnings per share
$0.80
Return on assets
6.96%
Return on equity
13.84%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.43×
Quick ratio
2.22×
Cash ratio
1.71×
Cash flow
Price / cash flow
1.23×
Price / free cash flow
1.25×
Free cash flow
$307.86M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CRMD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$54.52M
$101.93M
$127.43M
$128.62M
$104.28M
$39.74M
$39.08M
$31.21M
Cost of revenue
$24.52M
$24.81M
$22.31M
$21.31M
$11.2M
$1.86M
$1.6M
$1.18M
Gross profit
$30M
$77.13M
$105.12M
$107.31M
$93.08M
$37.87M
$37.49M
$30.03M
Selling, general and administrative
$29.59M
$27.53M
$34.25M
$39.58M
$36.64M
$15.89M
$14.17M
$15.37M
Research and development
$7.04M
$6.68M
$7.21M
$8.6M
$5.1M
$2.44M
$3.19M
$1.73M
Total operating expenses
$36.62M
$34.29M
$41.73M
$48.18M
$41.74M
$17.52M
$16.84M
$17.1M
Operating income
-$6.62M
$42.84M
$63.39M
$59.13M
$51.35M
$20.35M
$20.64M
$12.94M
Interest expense
$0
$0
$0
-$1.82M
$0
$0
$0
-$9.6K
Income before taxes
-$16.45M
$38.73M
$55.65M
$56.45M
$52.58M
$20.35M
$20.64M
$13.46M
Income taxes
-$1.73M
$12.75M
$17.04M
$42.43M
-$55.99M
$522K
$0
-$230
Net income
-$14.72M
$25.99M
$38.6M
$14.02M
$108.56M
$19.83M
$20.64M
$13.46M
Net income attributable to common shareholders
-$14.72M
$25.99M
$38.6M
$14.02M
$107.89M
$19.83M
$20.64M
$13.47M
EBITDA
$3.91M
$53.38M
$73.93M
$69.56M
$55.14M
$20.51M
$20.81M
$13.07M
Basic earnings per share
-$0.19
$0.33
$0.48
$0.18
$1.42
$0.29
$0.32
$0.22
Diluted earnings per share
-$0.19
$0.29
$0.43
$0.15
$1.26
$0.28
$0.30
$0.22
Recent news
Company coverage with links to the original publishers.
CorMedix (CRMD) reported a quarterly loss of $0.04 per share, beating consensus estimates of $0.09 loss by 55.56%, but revenues declined to $54.52 million from $104.28 million year-over-year. The stock has underperformed the market by 54.4% this year and carries a Zacks Rank #3 (Hold) rating. Techne (TECH), a peer in the medical testing industry, is expected to report earnings of $0.46 per share with modest revenue growth of 2.4%.
Kura Oncology reported a quarterly loss of $0.78 per share, beating the consensus estimate of $0.83 loss, with revenues of $22.84 million exceeding expectations by 2.87%. Despite the earnings beat, the stock has declined 27.1% year-to-date versus the S&P 500's 10.3% gain. The company holds a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends.
Immatics is expected to report flat earnings compared to the year-ago quarter with 68.8% revenue growth. The company has a positive Earnings ESP of +2.04% combined with a Zacks Rank #3, suggesting it will likely beat consensus EPS estimates. However, the company has a mixed earnings surprise history, missing estimates by 23.26% in the last reported quarter.
CorMedix is expected to report a year-over-year earnings decline with a quarterly loss of $0.09 per share and 49.7% revenue decline for Q3 2026. With a negative Earnings ESP of -44.44% and Zacks Rank #3, the stock is not positioned as a compelling earnings-beat candidate. Peer company Coherus Oncology faces similar challenges with a negative Earnings ESP of -1.54% despite a Zacks Rank #2 Buy rating.
In a comparison of two medical-biomedical stocks, CorMedix (CRMD) emerges as the superior value option over Prothena (PRTA). CRMD holds a Zacks Rank of #2 (Buy) with a Value grade of A, featuring a forward P/E of 13.48 and PEG ratio of 1.35. PRTA, ranked #3 (Hold) with a Value grade of F, has a forward P/E of 66.51 and PEG ratio of 1.99, indicating it is significantly more expensive relative to its growth prospects.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.